Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
11 p, 726.2 KB Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 / Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ; Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ; Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ; Muro, Kei (Aichi Cancer Center Hospital) ; Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ; Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ; Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ; Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ; Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ; Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ; Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ; Universitat Autònoma de Barcelona
In the primary analysis population (i. e. , PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. [...]
2021 - 10.1007/s10120-021-01200-w
Gastric Cancer, Vol. 24 (august 2021) , p. 1330-1340  
2.
9 p, 1.1 MB Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab / Fuchs, Charles S. (Harvard Medical School) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Tomášek, Jiří (Masaryk University (Czech Republic)) ; Chau, Ian (Royal Marsden Hospital (Regne Unit)) ; Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice (Czech Republic)) ; Safran, Howard (Brown University Oncology Research Group (USA)) ; Tehfe, Mustapha A. (Centre Hospitalier de Montréal (Canada)) ; Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ; Topuzov, Eldar (Northwest State Medical University na II Mechnikov) ; Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ; Udrea, Anghel Adrian (Medisprof SRL (Romania)) ; Campbell, William (Hospital Herrera Llerandi (Guatemala)) ; Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ; Emig, Michael (Lilly Deutschland GmbH (Germany)) ; Melemed, Symantha A. (Lilly Corporate Center (USA)) ; Hozak, Rebecca R. (Lilly Corporate Center (USA)) ; Ferry, David (Lilly Corporate Center (USA)) ; Caldwell, C. William (Lilly Corporate Center (USA)) ; Ajani, Jaffer A. (The University of Texas MD Anderson Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982  

Vegeu també: autors amb noms similars
2 Fuchs, C. F.
2 Fuchs, C. S.
1 Fuchs, C.S.
3 Fuchs, Charles
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.